Accessibility Menu
 
Aclaris Therapeutics logo

Aclaris Therapeutics

(NASDAQ) ACRS

Current Price$3.73
Market Cap$420.88M
Since IPO (2015)-68%
5 Year-86%
1 Year+145%
1 Month+31%

Aclaris Therapeutics Financials at a Glance

Market Cap

$420.88M

Revenue (TTM)

$7.83M

Net Income (TTM)

$64.92M

EPS (TTM)

$-0.53

P/E Ratio

-6.59

Dividend

$0.00

Beta (Volatility)

1.06 (Average)

Price

$3.73

Volume

29,951

Open

$3.52

Previous Close

$3.73

Daily Range

$3.52 - $3.77

52-Week Range

$1.05 - $4.89

ACRS: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Aclaris Therapeutics

Industry

Pharmaceuticals

Employees

73

CEO

Neal S. Walker, PhD, MBA

Headquarters

Wayne, PA 19087, US

ACRS Financials

Key Financial Metrics (TTM)

Gross Margin

73%

Operating Margin

-10%

Net Income Margin

-8%

Return on Equity

-50%

Return on Capital

-58%

Return on Assets

-40%

Earnings Yield

-15.17%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$420.88M

Shares Outstanding

120.59M

Volume

29.95K

Short Interest

0.00%

Avg. Volume

2.38M

Financials (TTM)

Gross Profit

$5.74M

Operating Income

$76.38M

EBITDA

$64.47M

Operating Cash Flow

$47.11M

Capital Expenditure

$111.00K

Free Cash Flow

$47.11M

Cash & ST Invst.

$90.75M

Total Debt

$2.12M

Aclaris Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$1.29M

-85.9%

Gross Profit

$2.10M

+2431.1%

Gross Margin

1.62%

N/A

Market Cap

$420.88M

N/A

Market Cap/Employee

$6.90M

N/A

Employees

61

N/A

Net Income

$19.80M

+79.5%

EBITDA

$19.69M

-41.4%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$88.64M

-22.0%

Accounts Receivable

$5.57M

+1650.0%

Inventory

$0.00

N/A

Long Term Debt

$1.56M

N/A

Short Term Debt

$551.00K

N/A

Return on Assets

-40.46%

N/A

Return on Invested Capital

-57.94%

N/A

Free Cash Flow

$13.09M

+70.8%

Operating Cash Flow

$13.13M

-46.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SENSSenseonics Holdings, Inc.
$6.66+7.77%
CABACabaletta Bio, Inc.
$2.69+8.91%
ALLOAllogene Therapeutics, Inc.
$2.44+9.91%
EDITEditas Medicine, Inc.
$2.47+10.76%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$41.68+0.10%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$7.55-0.11%
QQQInvesco QQQ Trust
$577.18+0.03%
INTCIntel
$44.13+0.07%

Questions About ACRS

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.